2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5080 Long-term clinical outcomes with tisagenlecleucel for pediatric-young adult (Ped-YA) B-cell acute lymphoblastic leukemia (B-ALL)

Amanda DiNofia, MD, Adriana Balduzzi, MD2, André Baruchel, MD3, Jochen Büchner Sr, MD, PhD4, Lucy E. Cain, MBBS FRACP5, Kara L. Davis, D.O.6, Barbara De Moerloose7, Hidefumi Hiramatsu, MD, PhD8, Emily Hsieh, MD9, Marianne Ifversen Sr, MD, PhD10, Samuel John, MD11, Katie Kane12, Joerg Krueger, MD13, Kris Mahadeo, MD, MPH14, Regina M. Myers, MD15, Eneida R Nemecek, MD, MS, MBA16, Christina Peters Sr, MD, PhD17, Muna Qayed, MD18, Susana Rives, MD19, Lauren M. Vernau, BA20, Rakesh Awasthi, PhD21, Wendy Chiang, MD22, Mathew Francis, MSc23, Andrea Jegerlehner, PhD24, Pritesh Patel, MD25, Jennifer Willert, MD26, Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA27, Stephan A Grupp, MD, PhD28
1 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
2 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, Milano-Bicocca University, Monza, Italy
3 Université Paris Cité, Paris, France, University Hospital Robert Debré (APHP), Paris, France
4 Oslo University Hospital, Oslo, Norway
5 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
6 Stanford University School of Medicine, Stanford, California, United States
7 Ghent University Hospital, Ghent, Belgium
8 Kyoto University, Kyoto, Japan
9 Children's Hospital Los Angeles Cancer and Blood Disease Institute, Los Angeles, California, United States, University of Southern California, Los Angeles, California, United States
10 Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
11 UT Southwestern Medical Center, Dallas, Texas, United States
12 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
13 The Hospital for Sick Children, Toronto, Ontario, Canada
14 Duke University, Durham, North Carolina, United States
15 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
16 Center for Hematological Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
17 St. Anna Children's Hospital, St. Anna Children's Cancer Research Institute, Vienna, Austria
18 Children’s Healthcare of Atlanta, Atlanta, Georgia, United States, Emory University, Atlanta, Georgia, United States
19 Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red De Enfermedades Raras (CIBERER), Madrid, Spain, Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu de Barcelona, Institut de Recerca Sant Joan de Déu, Leukemia; Pediatric Hematology Disorders, Developmental Tumors Biology Group, Barcelona, Spain
20 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
21 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
22 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
23 IQVIA, Reading, United Kingdom
24 Novartis Pharma AG, Basel, Switzerland
25 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
26 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
27 The University of Melbourne, Melbourne, Victoria, Australia
28 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

Introduction: CD19-directed chimeric antigen receptor (CAR)-T cell therapy has revolutionized the clinical management of Ped-YA B-ALL; long-term follow-up is needed to fully define the benefit-risk profile. PAVO (NCT02445222) is an ongoing, long-term follow-up study of patients (pts) who received CD19-directed CAR-T cell therapy as part of studies sponsored or supported by Novartis. Here we report the longest and largest follow-up to date for Ped-YA pts with relapsed or refractory (r/r) B-ALL who received tisagenlecleucel (tisa-cel) in clinical trials.

Methods: Ped-YA pts with r/r B-ALL treated with tisa-cel could enroll in PAVO after completion, or early discontinuation, of their respective clinical trials for a 15-year posttreatment follow-up, in alignment with health authority guidance. The primary objective of PAVO is to describe delayed adverse events (AEs) suspected to be tisa-cel related, specifically including new subsequent malignancies, serious infections, serious neurologic disorders, new or exacerbated autoimmune disorders, and new hematologic disorders. Secondary objectives include long-term efficacy, CAR-T cell persistence measured by qPCR, presence of replication-competent lentivirus (RCL), and lymphocyte levels. Data cutoff was March 11, 2025.

Results: A total of 496 Ped-YA pts with r/r B-ALL received a tisa-cel infusion across 7 clinical parent trials. Of these 496 pts, 201 pts enrolled in PAVO and met safety inclusion criteria. At the time of enrollment, 86% of pts were in remission, and 13% of pts had relapsed or progressive disease. Of the 173 pts who entered PAVO while in remission, 18% experienced relapse based on investigator assessment during follow-up. Among pts assessed for CAR persistence, transgene was detected in peripheral blood for as long as 11 years. During long-term follow-up, 42% experienced an AE suspected to be tisa-cel related. The most frequent tisa-cel–related AEs (≥5% of pts) occurring during long-term follow-up while on PAVO included hypogammaglobulinemia (24%; 1% grade 3/4), sinusitis (10%; no grade 3/4), pneumonia (8%; 5% grade 3/4), chronic sinusitis (7%; 0.5% grade 3/4), neutrophil count decrease (6%; 3% grade 3/4), and upper respiratory tract infection (5%; no grade 3/4). Twenty-four percent of pts experienced a tisa-cel–related AE >5 years after infusion. The most frequent AEs (≥5% of pts) occurring >5 years after tisa-cel infusion were hypogammaglobulinemia (9%; no grade 3/4), sinusitis (8%; no grade 3/4), and pneumonia (5%; 5% grade 3/4). Hypogammaglobulinemia may be underreported due to immunoglobulin replacement therapy for B-cell aplasia. Eight subsequent malignancies were reported including lineage switch/transformed acute myeloid leukemia (AML) (n=4), myelodysplastic syndrome (n=1), basal cell carcinoma (n=1), follicular thyroid cancer (n=1), and malignant melanoma (n=1). There were no subsequent T-cell malignancies. All subsequent malignancies were not considered tisa-cel related and, of those pts tested, CAR transgene was not detected. No RCL has been detected. As of data cutoff, 149/201 (74%) pts were still in active follow-up; death was reported in 42 pts, including 23 due to disease progression.

Conclusions: Long-term follow-up of Ped-YA pts treated with tisa-cel for r/r B-ALL demonstrated no new safety signals. Cellular kinetics indicate sustained persistence with transgene detectable in peripheral blood for up to 11 years. Ongoing monitoring in PAVO continues to evaluate long-term AEs.

Amanda DiNofia, MD: Novartis - Consultancy (Includes expert testimony)